Janssen had better Darzalex sales than expected in Q1
Outside the US, Darzalex sales are going so well that they are close to overtaking US sales for Q1. In total, sales amounted to USD 1.37, from which Genmab receives royalties.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
US pharmaceutical company Jansssen holds the rights for Darzalex, which was developed by Danish biotech firm Genmab and has had significantly better sales than expected in this year's first quarter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen receives new approval for Darzalex in Canada
For subscribers
